Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 2/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 8/20 | 0.43 |
| ▸ | JAK2 | O60674 | 8/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.42 |
| ▸ | FLT3 | P36888 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | TYK2 | P29597 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL461050 | 0.87 | FLT3 (0.44) | TGFBR1JAK2IRAK4FLT3JAK1 | |
| SCHEMBL401639 | 0.85 | FLT3 (0.41) | JAK2IRAK4FLT3JAK1TYK2 | |
| SCHEMBL10246668 | 0.84 | FLT3 (0.43) | NTRK1JAK2IRAK4FLT3TYK2 | |
| SCHEMBL13355580 | 0.82 | TGFBR1 (0.46) | TGFBR1NTRK1JAK2IRAK4PARP1 | |
| SCHEMBL21285357 | 0.82 | JAK2 (0.47) | TGFBR1NTRK1JAK2JAK1TYK2 | |
| SCHEMBL13355648 | 0.81 | TGFBR1 (0.57) | TGFBR1NTRK1JAK2IRAK4JAK1 | |
| SCHEMBL10190991 | 0.80 | PDE4B (0.47) | IRAK4FLT3TSHRTYK2 | |
| SCHEMBL30993352 | 0.80 | TGFBR1 (0.49) | TGFBR1NTRK1JAK2JAK1TYK2 | |
| SCHEMBL24607321 | 0.77 | NTRK1 (0.47) | TGFBR1NTRK1JAK2IRAK4TYK2 | |
| SCHEMBL26352050 | 0.77 | TGFBR1 (0.46) | TGFBR1NTRK1JAK2IRAK4JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637516-B2 | Compounds and compositions as TRK inhibitors | IRM LLC (BM) | 2014-01-28 | — | — | US | disclosed |
| EP-2614062-A1 | IMIDAZO [1, 2]PYRIDAZIN COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2013-07-17 | — | — | EP | disclosed |
| US-20120065184-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-03-15 | — | — | US | disclosed |
| WO-2012034091-A1 | IMIDAZO [1, 2] PYRIDAZIN COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-03-15 | — | — | WO | disclosed |
| WO-2012034095-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-03-15 | — | — | WO | disclosed |
| WO-2012034095-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065184-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | TNK2, CNKSR1, BMP2K | TGFBR1 1680/4885NTRK1 131/4885JAK2 615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.